Inventor profile of:

Marc Schiller

City:

Aachen

Country:

Germany

Published Applications:

16

Last publication date:

2025-09-25

Top Assignees for applications by Marc Schiller

The entities that hold a legal rights for patent applications filed by inventor Schiller Marc:

Recent patent applications by Schiller Marc

Marc Schiller from Aachen, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-25
US20250295596A1
Human necessities

MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL

#2 | 2025-07-17
US20250228775A1
Human necessities

ETHANOLIC RESINIFERATOXIN CONCENTRATE

#3 | 2020-07-09
US20200215003A1
Human necessities

PARENTERAL ADMINISTRATION OF TAPENTADOL

#4 | 2020-02-20
US20200054584A1
Human necessities

Aqueous pharmaceutical formulation of tapentadol for oral administration

#5 | 2018-12-27
US20180369151A1
Human necessities

MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL

#6 | 2018-05-17
US20180133174A1
Human necessities

Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol

#7 | 2018-05-10
US20180125800A1
Human necessities

Stable formulation for parenteral administration of tapentadol

#8 | 2016-12-15
US20160361294A1
Human necessities

Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine

#9 | 2016-12-01
US20160346229A1
Human necessities

Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol

#10 | 2016-09-29
US20160279078A1
Human necessities

Stable Formulation for Parenteral Administration of Tapentadol

#11 | 2016-08-04
US20160220516A1
Human necessities

Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration

#12 | 2016-04-21
US20160106688A1
Human necessities

Parenteral Administration of Tapentadol

#13 | 2015-04-23
US20150111939A1
Human necessities

Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine

#14 | 2013-01-24
US20130022670A1
Human necessities

Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration

#15 | 2012-09-06
US20120225950A1
Human necessities

Semisolid aqueous pharmaceutical composition containing tapentadol

#16 | 2012-02-09
US20120034297A1
Human necessities

Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

InventorID:

52598 ⎘